ACHIEVEMENTS• Merger between Hamlet Pharma AB and SelectImmune Pharma AB (two public companies) creating a combined company in drug development for the treatment and prevention of cancer and infectious diseases.• Due diligence activities to evaluate the feasibility and potential benefits of the merger between Hamlet Pharma AB and SelectImmune Pharma AB 2023.• Solid experience in IP and patent portfolio development. Secured an acquisition of patent rights for the treatment of tuberculosis.• Successfully raised 47 MSEK in funding (rights issue) from private equity and public investors.• Engaged in 2.2 MEUR EU Horizon funding (EIC Accelerator) grants. At the end of January 2023, Hamlet filed the final report of the work supported by this grant with achievements regarded as ‘‘Exceptional’’ by the European Commission.• Engaged with top international advisory firms to drive commercialization and partnering opportunities within the pharma/biotech sector for our lead drug assets at a global scale. • Developed PR/IR strategy, public press releases, newsletters, social media posts, homepage web development and press briefings in connection with quarterly reports.• Publication of 8 quarterly reports, 2 annual reports, and the execution of 3 annual general meetings.• Engaged in receiving IND & Fast Track Drug Designation from the FDA for Alpha1H, for patients with bladder cancer.• Solid experience in clinic studies. Three Phase II clinical studies ongoing.• Strategic engagement with a third-party Contract Development and Manufacturing Organization (CDMO) to enhance manufacturing capacity, reduce cost, reduce time-to-market, and ensure scalability of production for our lead drug asset.

Hamlet Pharma AB is a pharmaceutical drug development company with base in Lund, Sweden, listed on the Swedish stock exchange market Spotlight since 2015. The company has secured >239 million SEK in public (IPO), EU grants, non-dilutive and private funding.The company provide new cancer therapeutic solutions using newly discovered drug molecules targeting and killing cancer cells with great precision with reduced side effects in patients.The lead drug candidate Alpha1H acts with high efficiency without any detectable toxicity.

Tetra Pak Processing Systems AB. Project Management and External Innovation TeamResearch & Technology (R&T)Achievements:• Successfully initiated and led joint collaboration development projects with external companies and universities, including PepsiCo Inc., FrieslandCampina, Dupont Nutrition Biosciences Aps, Chalmers University of Technology, and Hamlet Pharma AB.• Coordinated cross-functional teams to achieve project milestones and deliverables within tight timelines and budgets in large complex company organisation structure.• Successfully contributed to the formulation of legal contracts, such as Joint development agreements, with several different parties.• Contributed to the development of intellectual property, including patent applications and publications in peer-reviewed journals.The work:• Overall responsible for the successful planning and execution of research and technology projects from start to end.• Present project progress and findings to stakeholders and senior leadership.• Responsible for development agreements with large global companies.• Lead technical project reviews in a group of technical specialists• Contribute with technical and scientific expertise within the food technology area.• Yearly project budget of 10-15 million SEK.

R&DProject Manager - Development: Managing Product Development projects according to a Toll Gate driven Product Development Process (PDP).Project Manager - Research: Managing multi center clinical trial investigations in Skåne within Hemo Dialysis. Focus on blood analysis, biochemical markers for inflammation.Specialist competence in Hemo Dialysis.Other experiences: CE marking, storage studies, Analytical Chemistry, Product launches, Clinical trial investigations, Business case calculations, Budget, Risk Management...

Managing Research projects in early R&D stage.Industrial Ph.D program with focus on biocompatibility of Peritoneal Dialysis Fluids.Present research results at several international conferences (ASN, ISPD).Educate sales departments and customers (Doctors and Nurses) in the area of Peritoneal Dialysis. Specialist competence: Analytical Chemistry and Laboratory instruments, Peritoneal Dialysis, Chemistry, Immunology, Oxidative stress, Advanced Glycation End Products, Glucose Degradation Products (GDPs).Publications:* Kjellstrand, P., M. Erixon, A. Wieslander, T. Linden and E. Martinson. Temperature: Single most important factor for degradation of glucose during storage. Peritoneal Dialysis International, 2004* Erixon, M., T. Linden, P. Kjellstrand, O. Carlsson, M. Ernebrant, G. Forsbäck, A. Wieslander and J.Å. Jönsson. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Peritoneal Dialysis International, 2004. * Erixon, M., A. Wieslander, T. Linden, O. Carlsson, G. Forsbäck, E. Svensson and J.Å. Jönsson and P. Kjellstrand. Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs. Peritoneal Dialysis International, 2005. * Erixon, M., A. Wieslander, T. Linden, O. Carlsson, G. Forsbäck, E. Svensson, J.Å. Jönsson, and P. Kjellstrand. How to avoid glucose degradation products in peritoneal dialysis fluids. Peritoneal Dialysis International, 2006.* Erixon, M., A. Wieslander, T. Linden, O. Carlsson, J.Å. Jönsson, Simonsen. O and P. Kjellstrand. 3,4-DGE in PD fluids cannot be found in plasma after infusion into the peritoneal cavity due to its high reactivity. Peritoneal Dialysis International, 2008. * Bryland, A., M. Broman, M. Erixon, H. Friberg, A. Wieslander, P. Kjellstrand, O. Carlsson and G. Godaly. Intravenous infusion fluids contain toxic glucose degradation products. Critical Care Medicine, 2010.